CVS Forms 3, 4 and 5: Stock Options | CVS HEALTH CORPORATION

CVS HEALTH CORPORATION Forms 3, 4 and 5: Stock Options

Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 8 rows in 2026. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.

2026-03-31: Reporting owner Shah Prem S; Form 4; Security Stock Option; Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
2026-03-31: Reporting owner Newman Brian; Form 4; Security Stock Option; Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
2026-03-31: Reporting owner Nelson Steven H; Form 4; Security Stock Option; Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
2026-03-31: Reporting owner Mandadi Tilak; Form 4; Security Stock Option; Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).

Purchase (P)Sale (S)All rows

CVS insiders transactions against the stock price

Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close

Logarithmic scale. Both lines share the same starting value for the selected range.

Markers: each transaction type positioned at that session's split-adjusted close. Tooltips retain the reported transaction price when available.

Transaction date	Reporting owner	Form	Security	Transaction	Shares	Price	Price that day	Filing
2026-03-31	Shah Prem S Officer (EVP and Group President)	4	Stock Option Derivative · Direct	A Grant, award or other acquisition pursuant to Rule 16b-3(d)	+161,676 161,676 owned after	$71.82	$71.82	2026-04-02
2026-03-31	Newman Brian Officer (EVP, Chief Financial Officer)	4	Stock Option Derivative · Direct	A Grant, award or other acquisition pursuant to Rule 16b-3(d)	+125,748 125,748 owned after	$71.82	$71.82	2026-04-02
2026-03-31	Nelson Steven H Officer (EVP and President, Aetna)	4	Stock Option Derivative · Direct	A Grant, award or other acquisition pursuant to Rule 16b-3(d)	+143,712 143,712 owned after	$71.82	$71.82	2026-04-02
2026-03-31	Mandadi Tilak Officer (EVP, Chief Exp & Tech Officer)	4	Stock Option Derivative · Direct	A Grant, award or other acquisition pursuant to Rule 16b-3(d)	+143,712 143,712 owned after	$71.82	$71.82	2026-04-02
2026-03-31	Khichi Samrat S. Officer (EVP, CPO and General Counsel)	4	Stock Option Derivative · Direct	A Grant, award or other acquisition pursuant to Rule 16b-3(d)	+80,838 80,838 owned after	$71.82	$71.82	2026-04-02
2026-03-31	Compton-Phillips Amy Officer (EVP, Chief Medical Officer)	4	Stock Option Derivative · Direct	A Grant, award or other acquisition pursuant to Rule 16b-3(d)	+35,928 35,928 owned after	$71.82	$71.82	2026-04-02
2026-03-31	Clark James David Officer (SVP, Cont & Chief Acct Officer)	4	Stock Option Derivative · Direct	A Grant, award or other acquisition pursuant to Rule 16b-3(d)	+11,976 11,976 owned after	$71.82	$71.82	2026-04-02
2026-03-31	CAPOZZI HEIDI B Officer (EVP and Chief People Officer)	4	Stock Option Derivative · Direct	A Grant, award or other acquisition pursuant to Rule 16b-3(d)	+64,670 64,670 owned after	$71.82	$71.82	2026-04-02

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
PETMED EXPRESS INC (PETS)	United States	$0.034B	-1.41